Veru Cash and Cash Equivalents Rise to $27.6 Million
Cash, cash equivalents and restricted cash were $27.6M as of March 31 versus $15.8M as of September 30, 2025. "We are extremely pleased with the progress of the enrollment of the Phase 2b PLATEAU clinical trial to evaluate the effect of enobosarm 3mg on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in older patients who have obesity and receiving a semaglutide GLP-1 RA treatment for weight reduction. We are on track for presenting the results of the interim analysis which is expected in Q1 calendar year 2027," said Mitchell Steiner, Chairman, President, and CEO of Veru.
